A multifaceted role of bisphosphonates from palliative care to anti-cancer therapy in solid tumors.
Sindhusha VeeraballiSai Samyuktha BandaruChrystina KiwanKok Hoe ChanHamid S ShaabanPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
This review article focuses on the antitumor activity of bisphosphonates, safety profile, and the role of bisphosphonates as preventive, neoadjuvant, and adjuvant chemotherapy. A significant improvement in overall survival and cancer-specific survival and recurrence-free survival with the usage of bisphosphonates is noted in breast cancer patients, particularly in post-menopausal women. Though great progress has been achieved in over 20 years, further research is needed to identify the subgroup of patients that are most likely to benefit from adjuvant bisphosphonate therapy and to determine regimens with greater efficacy and better safety profile.
Keyphrases
- free survival
- palliative care
- cancer therapy
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- early stage
- rectal cancer
- drug delivery
- polycystic ovary syndrome
- peritoneal dialysis
- randomized controlled trial
- squamous cell carcinoma
- clinical trial
- pregnant women
- young adults
- stem cells
- type diabetes
- skeletal muscle
- mesenchymal stem cells
- patient reported
- insulin resistance